Bize Ulaşın 0533 482 66 72

Uluslararası Çok Merkezli Klinik Çalışmalar

1. INVEST – The International Verapamil SR/Trandolapril Study – Co-investigator

2. EXTRACT-TIMI 25 – The Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment, Thrombolysis in Myocardial Infarction-Study 25 – Co-investigator

3. CURRENT (OASIS 7) – Randomized, Multinational, Double-Blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy. – Co-investigator

4. IMPROVE-IT – A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial – IMPROVE IT) – Principal Investigator

5. TRA-CER TRIAL – “A Multi-center, RandomizedDouble-Blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome – National Leader – Steering Committee Member

6. APPRAISE – 2: A Phase 3, Randomized, Double-Blind, Evaluation of Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome. Phase 3 trial. Principal Investigator

7. A randomized, double-blind , triple-dummy trial, to compare otamixaban to Unfractionated Heparin + eptifibatide, in patients with Unstable angina/Non ST segment Elevation Myocardial infarction scheduled to undergo an early invasive strategy. Phase 3 trial. Principal Investigator

8. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Safety Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus Treated with Dutogliptin. Phase 3 trial. Principal Investigator

9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular  outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome. Phase 3 trial. National Leader – Steering Committee Member

10. A comparison of platelet inhibition following a prasugrel 60mg or prasugrel 30mg loading dose with or without pretreatment with a clopidogrel 600mg loading dose in patients with acute coronary syndromes (ACS) who are to undergo percutaneous coronary intervention (PCI). Phase 2 trial. National Leader – Steering Committee Member

11. SOLID-TIMI 52. A clinical outcomes study of Darapladib versus placebo in subjects following acute coronary syndrome to compare the incidence of major adverse cardiovascular events. Phase 3 trial. Principal Investigator